Skip to main content

GSK to pay up to $3.3 billion for biopharma Affinivax

GSK PLC said Tuesday that it has agreed to buy clinical-stage biopharmaceutical company Affinivax, Inc. for up to $3.3 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.